Interestingly, this newsletter contains the first hint/trace/acknowledgment that I’ve seen by Starpharma, that the first 2 years of AstraZeneca in the clinic with AZD0466 was pretty much a dud after starting the trial up against solid cancers. AZ essentially started Phase 1 again last year trialling against other cancer types.
Newsletter today: “The leukemia trial replaces the first-in-human study in solid cancers, following AstraZeneca’s decision to focus initial development activities on haematological cancers…”
